Alzheimer Disease
Conditions
Brief summary
In this proposed study, the investigators will evaluate the efficacy, safety and related mechanism of sulforaphane in treatment of Alzheimer's disease (AD). The study will recruit 160 AD patients, and then these patients will be randomized to sulforaphane group or placebo group (80 patients per arm) for 24 weeks clinic trial. Clinical efficacy and safety assessment will be done at screen/baseline, 4 week, 12 week, and 24 week. The specific aims are to compare sulforaphane versus placebo on: clinical core symptoms; biological samples also will be collected, and stored to research related mechanisms. During the study period, safety index including blood and urine routine, liver and kidney function, coagulation index and clinical effect index about neuropsychological scales will be recorded.
Detailed description
In this proposed study, the investigators will evaluate the efficacy, safety and related mechanism of sulforaphane in treatment of AD. The study will recruit 160 AD patients, then these patients will be randomized to sulforaphane group or placebo group (80 patients per arm) for 24 weeks clinic trial. Clinical efficacy and safety assessment will be done at screen/baseline, 4 week, 12 week, 24 week. The specific aims are to compare sulforaphane versus placebo on: 1) clinical core symptoms; The investigators hypothesize that (1) sulforaphane is superior to placebo in the treatment of clinical symptoms in patients with AD, measured by the ADAS-cog, MMSE Scale, Moca; (2) Biological samples will be collected, and stored so that the hypothesis sulforaphane may alter oxidative stress indexes or inflammatory biomarkers, and influence histone deacetylase inhibitor mechanism or inflammatory mechanism et al that may be significantly correlated with clinical improvement. (3) Safety index including blood and urine routine, liver and kidney function, coagulation index and clinical effect index about neuropsychological scales will be recorded.
Interventions
DIETARY_SUPPLEMENTsulforaphane
Sulforaphane take 2550mg once a day.
DIETARY_SUPPLEMENTPlacebo
Placebo take 2550mg once a day.
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Age range from 50 to 75 (including 50 and 75 years old), regardless of ethnic group or gender; * 2\. The subjects should be able to complete the cognitive ability measurement and other tests specified in the protocol; * 3\. Meeting the criteria for likely Alzheimer's Disease （AD） dementia (2011) by National Institute of Neurological Disorders and Strokes - Alzheimer's Disease and Related Diseases Association（NINCDS-ADRDA）; * 4\. Patients with mild dementia: the total score of Mini-Mental State Examination (MMSE) : ≥22 points; Clinical Dementia Rating scale （CDR）score \> or equal to 0.5 and \< or equal to1；The MMSE score provides evidence of mild disease severity and the CDR-GS score indicates that the patients have noticeable amnestic (pAD) or cognitive and functional (mAD) deficits * 5\. The total score of the Hachinski Ischemic Score （HIS ）was \< 4. * 6\. Hamilton depression scale (17 items) total score ≤7 points; * 7\. Brain MRI shows a high likelihood of AD; * 8\. Before enrollment, patients should take a stable dose of dementia drugs (donepezil 5mg) ≥8 weeks; * 9\. The expected survival time is \> 1 year; * 10\. Subjects should have a stable and reliable caregiver, or at least have frequent contact with the caregiver (at least 3 days per week and at least 2 hours per day), who will help patients participate in the whole study; Caregivers must accompany the subjects to the visit and assist in completing the relevant scale.
Exclusion criteria
* 1\. Refuse to sign the inform consent form; * 2\. Other causes of dementia: known vascular, central nervous system infection ,Parkinson's disease, traumatic brain dementia, other physical and chemical factors; serious body disease , intracranial space-occupying lesions, endocrine system disease, such as thyroid disease, and a lack of vitamin B12, folic acid, or any other known causes of dementia. * 3\. Central nervous system diseases (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy, etc.); * 4\. Obvious positive signs of nervous system examination; * 5\. Psychotic patients, including schizophrenia or other disorders with bipolar disorder, major depression or delirium; * 6\. Uncontrolled hypertension or hypotension during screening: systolic blood pressure ≥180（millimetres of mercury ）mmHg or \< 90mmhg, or diastolic blood pressure ≥120mmHg or \< 60mmhg; * 7\. Unstable or severe diseases of the heart, lung, liver, kidney and hematopoietic system according to the judgment of the researchers; * 8\. Patients with incurable visual and auditory disorders that cannot complete neuropsychological tests and scales; * 9\. Female subjects who are positive in pregnancy test or breast-feeding and who cannot take effective contraceptive measures or have a birth plan; * 10\. Severe allergy, non-allergic drug reaction or multi-drug allergy history; * 11\. Participated in other clinical trials within 3 months before screening visit; * 12\. Taking any health care products related to brain and brain improvement currently and failing to keep the promise to stop using the above products; * 13\. Other conditions are unsuitable for participating in this study according to the judgement of researchers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Alzheimer's Disease Assessment Scale | From baseline to 24 weeks | The Alzheimer's Disease Assessment Scale (ADAS-cog) will be performed to test the cognition of patients at the enrollment, week 12 and week 24. The score ranges from 0 to 75，and higher values represent a better outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Alzheimer's Disease Collaborative research group-Activities of Daily Living scores. | From baseline to 24 weeks | Alzheimer's Disease Collaborative research group-Activities of Daily Living scores (ADCS-ADL) will be performed to test the activities of patients at the enrollment,week 6 and week12.The score ranges from 0 to 54，and higher values represent a better outcome. |
| Neuropsychiatric Inventory scores | baseline time to 24 weeks | Neuropsychiatric Inventory scores (NPI) will be performed to test the mental symptoms of patients at the enrollment and week12.The score ranges from 0 to 144，and higher values represent a worse outcome. |
| Mini-Mental State Examination scores | baseline time to 24 weeks | Mini-Mental State Examination scores(MMSE) will be performed to test the cognition of patients at the enrollment and week12.The score ranges from 0 to 30，and higher values represent a better outcome. |
| Montreal Cognitive Assessment scores | baseline time to 24 weeks | Montreal Cognitive Assessment scores (MoCA) will be performed to test the cognition of patients at the enrollment and week12.The score ranges from 0 to 30，and higher values represent a better outcome. |
| Clinician Interview-Based Impression of Change plus caregiver input | baseline time to 24 weeks | Clinician Interview-Based Impression of Change plus caregiver input (CIBIC-plus) is widely used in antidementia drug trials. It comprises Likert scales for disease severity and changes, and written accounts summarizing semistructured interviews evaluating behavior, cognition, and function. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Oxidative stress indexes | At baseline and 24 week/endpoint | The change of Oxidative stress indexes as tested by Oxidative stress indexes detection kit |
| Epigenetics indicators | At baseline and 24 week/endpoint | The change of Epigenetics indicators as tested by Epigenetics indicators |
| Cytokines & Chemokines | At baseline and 24 week/endpoint | The change of Cytokines & Chemokines as tested by Cytokines & Chemokines detection kit |
| Metabolites | At baseline and 24 week/endpoint | The change of Metabolites as tested by Metabolites detection kit |
| RNA expression | At baseline and 24 week/endpoint | The change of RNA expression as tested by RNA expression detection kit |
| Intestinal microflora | At baseline and 24 week/endpoint | The change of intestinal microflora as tested by Metagenomic technique |
Countries
China
Contacts
Primary ContactQing-Qing tao, Ph.D
Outcome results
None listed